APO Research
Talk to an analyst

APO RESEARCH · REPORT

Acute Vulvovaginal Candidiasis Treatment

Compare research editions
View pricing & licenses

Selected research

Industry Research

Acute Vulvovaginal Candidiasis Treatment Industry Research Report 2026

20 December 2025139 pages

Choose your research edition.

Industry ResearchAcute Vulvovaginal Candidiasis Treatment Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Acute Vulvovaginal Candidiasis Treatment Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Acute Vulvovaginal Candidiasis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acute Vulvovaginal Candidiasis Treatment Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Acute Vulvovaginal Candidiasis Treatment Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Acute Vulvovaginal Candidiasis Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Acute Vulvovaginal Candidiasis Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Acute Vulvovaginal Candidiasis Treatment market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Acute Vulvovaginal Candidiasis Treatment market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Acute Vulvovaginal Candidiasis Treatment include Sandoz International GmbH, Novartis AG, Mylan N.V., Pfizer, Inc., Bayer AG., Scynexis, Inc, Phathom Pharmaceutical, Inc, Pacgen Life Science Corporation and NovaDigm Therapeutics, Inc, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Acute Vulvovaginal Candidiasis Treatment market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Acute Vulvovaginal Candidiasis Treatment.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Acute Vulvovaginal Candidiasis Treatment Market by Company

Sandoz International GmbH

Novartis AG

Mylan N.V.

Pfizer, Inc.

Bayer AG.

Scynexis, Inc

Phathom Pharmaceutical, Inc

Pacgen Life Science Corporation

NovaDigm Therapeutics, Inc

Mycovia Pharmaceuticals, Inc

Lupin

Grupo Ferrer Internacional, S.A

Cidara Therapeutics, Inc

Cadila Pharmaceuticals

Bristol-Myers Squibb Company

Basilea Pharmaceutica Ltd

Astellas Pharma Inc

Amplyx Pharmaceuticals Inc

Amneal Pharmaceuticals LLC

Accord Healthcare Ltd

Acute Vulvovaginal Candidiasis Treatment Segment by Type

Nystatin

Ketoconazole

Terconazole

Terbinafine

Clotrimazole

Fluconazole

Others

Acute Vulvovaginal Candidiasis Treatment Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Acute Vulvovaginal Candidiasis Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Vulvovaginal Candidiasis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acute Vulvovaginal Candidiasis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Vulvovaginal Candidiasis Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Acute Vulvovaginal Candidiasis Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2021-2026) Table 7. Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Type (2027-2032) Table 9. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2021-2026) Table 11. Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Application (2027-2032) Table 13. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Region (2021-2026) Table 16. Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Region (2027-2032) Table 18. Acute Vulvovaginal Candidiasis Treatment Industry Trends Table 19. Acute Vulvovaginal Candidiasis Treatment Industry Drivers Table 20. Acute Vulvovaginal Candidiasis Treatment Industry Opportunities and Challenges Table 21. Acute Vulvovaginal Candidiasis Treatment Market Restraints Table 22. Global Top Acute Vulvovaginal Candidiasis Treatment Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Players (2021-2026) Table 24. Global Acute Vulvovaginal Candidiasis Treatment Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Acute Vulvovaginal Candidiasis Treatment, Headquarters and Area Served Table 26. Global Acute Vulvovaginal Candidiasis Treatment Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Acute Vulvovaginal Candidiasis Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2027-2032) & (US$ Million) Table 45. Sandoz International GmbH Company Information Table 46. Sandoz International GmbH Business Overview Table 47. Sandoz International GmbH Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 48. Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 49. Sandoz International GmbH Recent Developments Table 50. Novartis AG Company Information Table 51. Novartis AG Business Overview Table 52. Novartis AG Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 53. Novartis AG Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 54. Novartis AG Recent Developments Table 55. Mylan N.V. Company Information Table 56. Mylan N.V. Business Overview Table 57. Mylan N.V. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 58. Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 59. Mylan N.V. Recent Developments Table 60. Pfizer, Inc. Company Information Table 61. Pfizer, Inc. Business Overview Table 62. Pfizer, Inc. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 63. Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 64. Pfizer, Inc. Recent Developments Table 65. Bayer AG. Company Information Table 66. Bayer AG. Business Overview Table 67. Bayer AG. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 68. Bayer AG. Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 69. Bayer AG. Recent Developments Table 70. Scynexis, Inc Company Information Table 71. Scynexis, Inc Business Overview Table 72. Scynexis, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 73. Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 74. Scynexis, Inc Recent Developments Table 75. Phathom Pharmaceutical, Inc Company Information Table 76. Phathom Pharmaceutical, Inc Business Overview Table 77. Phathom Pharmaceutical, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 78. Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 79. Phathom Pharmaceutical, Inc Recent Developments Table 80. Pacgen Life Science Corporation Company Information Table 81. Pacgen Life Science Corporation Business Overview Table 82. Pacgen Life Science Corporation Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 83. Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 84. Pacgen Life Science Corporation Recent Developments Table 85. NovaDigm Therapeutics, Inc Company Information Table 86. NovaDigm Therapeutics, Inc Business Overview Table 87. NovaDigm Therapeutics, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 88. NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 89. NovaDigm Therapeutics, Inc Recent Developments Table 90. Mycovia Pharmaceuticals, Inc Company Information Table 91. Mycovia Pharmaceuticals, Inc Business Overview Table 92. Mycovia Pharmaceuticals, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 93. Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 94. Mycovia Pharmaceuticals, Inc Recent Developments Table 95. Lupin Company Information Table 96. Lupin Business Overview Table 97. Lupin Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 98. Lupin Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 99. Lupin Recent Developments Table 100. Grupo Ferrer Internacional, S.A Company Information Table 101. Grupo Ferrer Internacional, S.A Business Overview Table 102. Grupo Ferrer Internacional, S.A Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 103. Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 104. Grupo Ferrer Internacional, S.A Recent Developments Table 105. Cidara Therapeutics, Inc Company Information Table 106. Cidara Therapeutics, Inc Business Overview Table 107. Cidara Therapeutics, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 108. Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 109. Cidara Therapeutics, Inc Recent Developments Table 110. Cadila Pharmaceuticals Company Information Table 111. Cadila Pharmaceuticals Business Overview Table 112. Cadila Pharmaceuticals Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 113. Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 114. Cadila Pharmaceuticals Recent Developments Table 115. Bristol-Myers Squibb Company Company Information Table 116. Bristol-Myers Squibb Company Business Overview Table 117. Bristol-Myers Squibb Company Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 118. Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 119. Bristol-Myers Squibb Company Recent Developments Table 120. Basilea Pharmaceutica Ltd Company Information Table 121. Basilea Pharmaceutica Ltd Business Overview Table 122. Basilea Pharmaceutica Ltd Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 123. Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 124. Basilea Pharmaceutica Ltd Recent Developments Table 125. Astellas Pharma Inc Company Information Table 126. Astellas Pharma Inc Business Overview Table 127. Astellas Pharma Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 128. Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 129. Astellas Pharma Inc Recent Developments Table 130. Amplyx Pharmaceuticals Inc Company Information Table 131. Amplyx Pharmaceuticals Inc Business Overview Table 132. Amplyx Pharmaceuticals Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 133. Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 134. Amplyx Pharmaceuticals Inc Recent Developments Table 135. Amneal Pharmaceuticals LLC Company Information Table 136. Amneal Pharmaceuticals LLC Business Overview Table 137. Amneal Pharmaceuticals LLC Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 138. Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 139. Amneal Pharmaceuticals LLC Recent Developments Table 140. Accord Healthcare Ltd Company Information Table 141. Accord Healthcare Ltd Business Overview Table 142. Accord Healthcare Ltd Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) & (US$ Million) Table 143. Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio Table 144. Accord Healthcare Ltd Recent Developments Table 145. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Acute Vulvovaginal Candidiasis Treatment Product Image Figure 5. Global Acute Vulvovaginal Candidiasis Treatment Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Type: 2025 VS 2032 Figure 7. Nystatin Product Figure 8. Ketoconazole Product Figure 9. Terconazole Product Figure 10. Terbinafine Product Figure 11. Clotrimazole Product Figure 12. Fluconazole Product Figure 13. Others Product Figure 14. Global Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Application: 2025 VS 2032 Figure 16. Retail Pharmacies Product Figure 17. Online Pharmacies Product Figure 18. Hospital Pharmacies Product Figure 19. Global Acute Vulvovaginal Candidiasis Treatment Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 20. Global Acute Vulvovaginal Candidiasis Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 21. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Region: 2025 VS 2032 Figure 22. Global Acute Vulvovaginal Candidiasis Treatment Market Share by Players in 2025 Figure 23. Global Acute Vulvovaginal Candidiasis Treatment Manufacturers Established Date Figure 24. Global Top 5 and 10 Acute Vulvovaginal Candidiasis Treatment Players Market Share by Revenue in 2025 Figure 25. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. North America Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2032) Figure 28. United States Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Canada Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. Mexico Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2032) Figure 31. Europe Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2032) Figure 33. Germany Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. France Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. U.K. Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Italy Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Spain Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Russia Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Netherlands Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. Nordic Countries Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2032) Figure 43. China Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. Japan Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. South Korea Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. India Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. India Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2032) Figure 48. Australia Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. China Taiwan Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Southeast Asia Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. South America Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. South America Acute Vulvovaginal Candidiasis Treatment Market Share by Country (2021-2032) Figure 53. Brazil Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 54. Argentina Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 55. Chile Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 56. Colombia Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 57. Peru Acute Vulvovaginal Candidiasis Treatment Market Size YoY Growth (2021-2032) & (US$ Million) Figure 58. Sandoz International GmbH Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) Figure 59. Novartis AG Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) Figure 60. Mylan N.V. Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) Figure 61. Pfizer, Inc. Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) Figure 62. Bayer AG. Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) Figure 63. Scynexis, Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) Figure 64. Phathom Pharmaceutical, Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) Figure 65. Pacgen Life Science Corporation Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) Figure 66. NovaDigm Therapeutics, Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) Figure 67. Mycovia Pharmaceuticals, Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) Figure 68. Lupin Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) Figure 69. Grupo Ferrer Internacional, S.A Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) Figure 70. Cidara Therapeutics, Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) Figure 71. Cadila Pharmaceuticals Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) Figure 72. Bristol-Myers Squibb Company Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) Figure 73. Basilea Pharmaceutica Ltd Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) Figure 74. Astellas Pharma Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) Figure 75. Amplyx Pharmaceuticals Inc Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) Figure 76. Amneal Pharmaceuticals LLC Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026) Figure 77. Accord Healthcare Ltd Revenue Growth Rate in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)

Scope & coverage.

Types
  • Nystatin
  • Ketoconazole
  • Terconazole
  • Terbinafine
  • Clotrimazole
  • Fluconazole
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Sandoz International GmbH
  • Novartis AG
  • Mylan N.V.
  • Pfizer, Inc.
  • Bayer AG.
  • Scynexis, Inc
  • Phathom Pharmaceutical, Inc
  • Pacgen Life Science Corporation
  • NovaDigm Therapeutics, Inc
  • Mycovia Pharmaceuticals, Inc
  • Lupin
  • Grupo Ferrer Internacional, S.A
  • Cidara Therapeutics, Inc
  • Cadila Pharmaceuticals
  • Bristol-Myers Squibb Company
  • Basilea Pharmaceutica Ltd
  • Astellas Pharma Inc
  • Amplyx Pharmaceuticals Inc
  • Amneal Pharmaceuticals LLC
  • Accord Healthcare Ltd

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Acute Vulvovaginal Candidiasis Treatment by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 Nystatin
  5. 2.2.3 Ketoconazole
  6. 2.2.4 Terconazole
  7. 2.2.5 Terbinafine
  8. 2.2.6 Clotrimazole
  9. 2.2.7 Fluconazole
  10. 2.2.8 Others
  11. 2.3 Acute Vulvovaginal Candidiasis Treatment by Application
  12. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.3.2 Retail Pharmacies
  14. 2.3.3 Online Pharmacies
  15. 2.3.4 Hospital Pharmacies
  16. 2.4 Assumptions and Limitations
3 Acute Vulvovaginal Candidiasis Treatment Breakdown Data by Type
  1. 3.1 Global Acute Vulvovaginal Candidiasis Treatment Historic Market Size by Type (2021-2026)
  2. 3.2 Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Type (2027-2032)
4 Acute Vulvovaginal Candidiasis Treatment Breakdown Data by Application
  1. 4.1 Global Acute Vulvovaginal Candidiasis Treatment Historic Market Size by Application (2021-2026)
  2. 4.2 Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Acute Vulvovaginal Candidiasis Treatment Market Perspective (2021-2032)
  2. 5.2 Global Acute Vulvovaginal Candidiasis Treatment Growth Trends by Region
  3. 5.2.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Acute Vulvovaginal Candidiasis Treatment Historic Market Size by Region (2021-2026)
  5. 5.2.3 Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Region (2027-2032)
  6. 5.3 Acute Vulvovaginal Candidiasis Treatment Market Dynamics
  7. 5.3.1 Acute Vulvovaginal Candidiasis Treatment Industry Trends
  8. 5.3.2 Acute Vulvovaginal Candidiasis Treatment Market Drivers
  9. 5.3.3 Acute Vulvovaginal Candidiasis Treatment Market Challenges
  10. 5.3.4 Acute Vulvovaginal Candidiasis Treatment Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Acute Vulvovaginal Candidiasis Treatment Players by Revenue
  2. 6.1.1 Global Top Acute Vulvovaginal Candidiasis Treatment Players by Revenue (2021-2026)
  3. 6.1.2 Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Acute Vulvovaginal Candidiasis Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Acute Vulvovaginal Candidiasis Treatment Head Office and Area Served
  6. 6.4 Global Acute Vulvovaginal Candidiasis Treatment Players, Product Type & Application
  7. 6.5 Global Acute Vulvovaginal Candidiasis Treatment Manufacturers Established Date
  8. 6.6 Global Acute Vulvovaginal Candidiasis Treatment Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032)
  2. 7.2 North America Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026)
  4. 7.4 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032)
  2. 8.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026)
  4. 8.4 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032)
  2. 9.2 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032)
  2. 10.2 South America Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026)
  4. 10.4 South America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size (2021-2032)
  2. 11.2 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Sandoz International GmbH
  2. 12.1.1 Sandoz International GmbH Company Information
  3. 12.1.2 Sandoz International GmbH Business Overview
  4. 12.1.3 Sandoz International GmbH Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  5. 12.1.4 Sandoz International GmbH Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  6. 12.1.5 Sandoz International GmbH Recent Developments
  7. 12.2 Novartis AG
  8. 12.2.1 Novartis AG Company Information
  9. 12.2.2 Novartis AG Business Overview
  10. 12.2.3 Novartis AG Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  11. 12.2.4 Novartis AG Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  12. 12.2.5 Novartis AG Recent Developments
  13. 12.3 Mylan N.V.
  14. 12.3.1 Mylan N.V. Company Information
  15. 12.3.2 Mylan N.V. Business Overview
  16. 12.3.3 Mylan N.V. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  17. 12.3.4 Mylan N.V. Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  18. 12.3.5 Mylan N.V. Recent Developments
  19. 12.4 Pfizer, Inc.
  20. 12.4.1 Pfizer, Inc. Company Information
  21. 12.4.2 Pfizer, Inc. Business Overview
  22. 12.4.3 Pfizer, Inc. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  23. 12.4.4 Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  24. 12.4.5 Pfizer, Inc. Recent Developments
  25. 12.5 Bayer AG.
  26. 12.5.1 Bayer AG. Company Information
  27. 12.5.2 Bayer AG. Business Overview
  28. 12.5.3 Bayer AG. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  29. 12.5.4 Bayer AG. Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  30. 12.5.5 Bayer AG. Recent Developments
  31. 12.6 Scynexis, Inc
  32. 12.6.1 Scynexis, Inc Company Information
  33. 12.6.2 Scynexis, Inc Business Overview
  34. 12.6.3 Scynexis, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  35. 12.6.4 Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  36. 12.6.5 Scynexis, Inc Recent Developments
  37. 12.7 Phathom Pharmaceutical, Inc
  38. 12.7.1 Phathom Pharmaceutical, Inc Company Information
  39. 12.7.2 Phathom Pharmaceutical, Inc Business Overview
  40. 12.7.3 Phathom Pharmaceutical, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  41. 12.7.4 Phathom Pharmaceutical, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  42. 12.7.5 Phathom Pharmaceutical, Inc Recent Developments
  43. 12.8 Pacgen Life Science Corporation
  44. 12.8.1 Pacgen Life Science Corporation Company Information
  45. 12.8.2 Pacgen Life Science Corporation Business Overview
  46. 12.8.3 Pacgen Life Science Corporation Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  47. 12.8.4 Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  48. 12.8.5 Pacgen Life Science Corporation Recent Developments
  49. 12.9 NovaDigm Therapeutics, Inc
  50. 12.9.1 NovaDigm Therapeutics, Inc Company Information
  51. 12.9.2 NovaDigm Therapeutics, Inc Business Overview
  52. 12.9.3 NovaDigm Therapeutics, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  53. 12.9.4 NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  54. 12.9.5 NovaDigm Therapeutics, Inc Recent Developments
  55. 12.10 Mycovia Pharmaceuticals, Inc
  56. 12.10.1 Mycovia Pharmaceuticals, Inc Company Information
  57. 12.10.2 Mycovia Pharmaceuticals, Inc Business Overview
  58. 12.10.3 Mycovia Pharmaceuticals, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  59. 12.10.4 Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  60. 12.10.5 Mycovia Pharmaceuticals, Inc Recent Developments
  61. 12.11 Lupin
  62. 12.11.1 Lupin Company Information
  63. 12.11.2 Lupin Business Overview
  64. 12.11.3 Lupin Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  65. 12.11.4 Lupin Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  66. 12.11.5 Lupin Recent Developments
  67. 12.12 Grupo Ferrer Internacional, S.A
  68. 12.12.1 Grupo Ferrer Internacional, S.A Company Information
  69. 12.12.2 Grupo Ferrer Internacional, S.A Business Overview
  70. 12.12.3 Grupo Ferrer Internacional, S.A Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  71. 12.12.4 Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  72. 12.12.5 Grupo Ferrer Internacional, S.A Recent Developments
  73. 12.13 Cidara Therapeutics, Inc
  74. 12.13.1 Cidara Therapeutics, Inc Company Information
  75. 12.13.2 Cidara Therapeutics, Inc Business Overview
  76. 12.13.3 Cidara Therapeutics, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  77. 12.13.4 Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  78. 12.13.5 Cidara Therapeutics, Inc Recent Developments
  79. 12.14 Cadila Pharmaceuticals
  80. 12.14.1 Cadila Pharmaceuticals Company Information
  81. 12.14.2 Cadila Pharmaceuticals Business Overview
  82. 12.14.3 Cadila Pharmaceuticals Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  83. 12.14.4 Cadila Pharmaceuticals Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  84. 12.14.5 Cadila Pharmaceuticals Recent Developments
  85. 12.15 Bristol-Myers Squibb Company
  86. 12.15.1 Bristol-Myers Squibb Company Company Information
  87. 12.15.2 Bristol-Myers Squibb Company Business Overview
  88. 12.15.3 Bristol-Myers Squibb Company Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  89. 12.15.4 Bristol-Myers Squibb Company Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  90. 12.15.5 Bristol-Myers Squibb Company Recent Developments
  91. 12.16 Basilea Pharmaceutica Ltd
  92. 12.16.1 Basilea Pharmaceutica Ltd Company Information
  93. 12.16.2 Basilea Pharmaceutica Ltd Business Overview
  94. 12.16.3 Basilea Pharmaceutica Ltd Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  95. 12.16.4 Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  96. 12.16.5 Basilea Pharmaceutica Ltd Recent Developments
  97. 12.17 Astellas Pharma Inc
  98. 12.17.1 Astellas Pharma Inc Company Information
  99. 12.17.2 Astellas Pharma Inc Business Overview
  100. 12.17.3 Astellas Pharma Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  101. 12.17.4 Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  102. 12.17.5 Astellas Pharma Inc Recent Developments
  103. 12.18 Amplyx Pharmaceuticals Inc
  104. 12.18.1 Amplyx Pharmaceuticals Inc Company Information
  105. 12.18.2 Amplyx Pharmaceuticals Inc Business Overview
  106. 12.18.3 Amplyx Pharmaceuticals Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  107. 12.18.4 Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  108. 12.18.5 Amplyx Pharmaceuticals Inc Recent Developments
  109. 12.19 Amneal Pharmaceuticals LLC
  110. 12.19.1 Amneal Pharmaceuticals LLC Company Information
  111. 12.19.2 Amneal Pharmaceuticals LLC Business Overview
  112. 12.19.3 Amneal Pharmaceuticals LLC Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  113. 12.19.4 Amneal Pharmaceuticals LLC Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  114. 12.19.5 Amneal Pharmaceuticals LLC Recent Developments
  115. 12.20 Accord Healthcare Ltd
  116. 12.20.1 Accord Healthcare Ltd Company Information
  117. 12.20.2 Accord Healthcare Ltd Business Overview
  118. 12.20.3 Accord Healthcare Ltd Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2021-2026)
  119. 12.20.4 Accord Healthcare Ltd Acute Vulvovaginal Candidiasis Treatment Product Portfolio
  120. 12.20.5 Accord Healthcare Ltd Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst